Home › Funds › BRAIDWELL LP › CLYM
BRAIDWELL LP position in CLYM
CLIMB BIO INC · Health Care
BRAIDWELL LP reported holding 2,797,375 shares of CLYM (CLIMB BIO INC) in its Q2 2026 13F filing — a position valued at US$36.5M, representing 1.44% of its reported portfolio and ranking #25 among its reported holdings. BRAIDWELL LP has disclosed CLYM holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How BRAIDWELL LP's CLYM position evolved
BRAIDWELL LP first disclosed a stake in CLYM in Q1 2026 at 1,529,675 shares (US$10.5M). The position peaked in Q2 2026 at 2,797,375 shares, worth US$36.5M. Across 2 filings, BRAIDWELL LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 2,797,375 shares valued at US$36.5M — an increase of 1,267,700 shares quarter over quarter.. Notable position changes include a 83% increase in Q2 2026 (shares fell 12% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 1.53M | $10.48M | New |
| Q2 2026 | 2.80M | $36.48M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CLYM and 13F data
CLYM (CLIMB BIO INC) is a Health Care company. 75 other funds we track also report a position in CLYM — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$147.4M), Cormorant Asset Management, LP (US$27.5M), Redmile Group, LLC (US$16.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CLYM
- RA CAPITAL MANAGEMENT, L.P. 11.30M sh · $147.36M · Q2 2026
- Cormorant Asset Management, LP 2.11M sh · $27.46M · Q2 2026
- Redmile Group, LLC 1.23M sh · $15.99M · Q2 2026
- GREAT POINT PARTNERS LLC 1.00M sh · $13.04M · Q2 2026
- Affinity Asset Advisors, LLC 972.00K sh · $12.67M · Q2 2026
- ADAR1 Capital Management, LLC 822.65K sh · $10.73M · Q2 2026
- STEMPOINT CAPITAL LP 742.75K sh · $9.69M · Q2 2026
- Parkman Healthcare Partners LLC 563.48K sh · $7.35M · Q2 2026
- SUPERSTRING CAPITAL MANAGEMENT LP 521.08K sh · $6.79M · Q2 2026
- SPHERA FUNDS MANAGEMENT LTD. 483.75K sh · $6.31M · Q2 2026
- NAN FUNG TRINITY (HK) Ltd 360.65K sh · $4.70M · Q2 2026
- Ally Bridge Group (NY) LLC 249.17K sh · $3.25M · Q2 2026
More on BRAIDWELL LP
FAQ
How long has BRAIDWELL LP held CLYM?
BRAIDWELL LP has disclosed CLYM holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is BRAIDWELL LP's current position in CLYM?
As of Q2 2026, BRAIDWELL LP holds 2.80M shares of CLYM (CLIMB BIO INC), valued at $36.48M, representing 1.44% of its reported portfolio and ranking #25.
Has BRAIDWELL LP been buying or selling CLYM?
In the latest 13F filing (Q2 2026), BRAIDWELL LP increased its position in CLYM. The position peaked in Q2 2026 at 2.80M shares.
Which other funds hold CLYM?
Other major institutional holders of CLYM include RA CAPITAL MANAGEMENT, L.P., Cormorant Asset Management, LP, Redmile Group, LLC, among 75 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.